HCM logo

HUTCHMED (China) Limited (HCM) Company Overview

Profile

Full Name:

HUTCHMED (China) Limited

Sector:

Healthcare

Country:

Hong Kong

IPO:

March 16, 2016

Indexes:

Not included

Description:

HUTCHMED (China) Limited is a biopharmaceutical company focused on developing and commercializing innovative medicines for cancer and other diseases. It operates in China and globally, emphasizing research and development to address unmet medical needs, particularly in oncology and immunotherapy.

Key Details

Price

$13.24

Annual Revenue

$838.00 M(+96.52% YoY)

Annual EPS

$0.60(+127.91% YoY)

Beta

0.80

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Jul 31, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

May 30, 2019

Analyst ratings

Recent major analysts updates

Aug 1, 24 Goldman Sachs
Neutral
Nov 24, 23 Deutsche Bank
Buy
Nov 10, 23 Goldman Sachs
Neutral
Sep 5, 23 Cantor Fitzgerald
Overweight
Jul 24, 23 Cantor Fitzgerald
Overweight
Aug 9, 22 Goldman Sachs
Neutral
Aug 2, 22 Goldman Sachs
Neutral
Sep 22, 21 Goldman Sachs
Neutral
Aug 3, 21 Jefferies
Buy
Mar 13, 20 Cantor Fitzgerald
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
HCM
globenewswire.comJanuary 13, 2025

— Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products Administration (“NMPA”) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with MET exon 14 skipping alteration.

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Paycor HCM, Inc. - PYCR
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Paycor HCM, Inc. - PYCR
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Paycor HCM, Inc. - PYCR
HCM
prnewswire.comJanuary 7, 2025

NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Paycor HCM, Inc. (NYSE: PYCR ), relating to the proposed merger with Paychex.

Jay Whitehead Joins Asure as Senior Vice President of AsurePay(TM) and Marketplace
Jay Whitehead Joins Asure as Senior Vice President of AsurePay(TM) and Marketplace
Jay Whitehead Joins Asure as Senior Vice President of AsurePay(TM) and Marketplace
HCM
globenewswire.comJanuary 7, 2025

Seasoned executive, entrepreneur, and HCM thought leader to drive innovation and foster strategy partnerships at fast-growing payroll provider Seasoned executive, entrepreneur, and HCM thought leader to drive innovation and foster strategy partnerships at fast-growing payroll provider

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
HCM
globenewswire.comJanuary 1, 2025

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”). ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. This acceptance also triggers a milestone payment from AstraZeneca.

Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales
Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales
Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales
HCM
reuters.comJanuary 1, 2025

Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship conglomerate look to ramp up capital and pivot towards core operations at the drugmaker.

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
HCM
globenewswire.comJanuary 1, 2025

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —

Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
HCM
globenewswire.comDecember 30, 2024

SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Paycor HCM: Positive On The Mid-Term Growth Outlook (Rating Upgrade)
Paycor HCM: Positive On The Mid-Term Growth Outlook (Rating Upgrade)
Paycor HCM: Positive On The Mid-Term Growth Outlook (Rating Upgrade)
HCM
seekingalpha.comDecember 25, 2024

I am upgrading PYCR to a buy rating due to optimistic mid-term guidance and strong earnings growth potential. PYCR's new guidance indicates sustainable mid-teens recurring revenue growth and >800 bps adj EBIT margin expansion, driving >20% adj EBIT growth. Successful upmarket traction, increased sales headcount, and strong broker relationships are key drivers of PYCR's positive outlook.

Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
HCM
globenewswire.comDecember 23, 2024

SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
HCM
globenewswire.comDecember 19, 2024

SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

FAQ

  • What is the ticker symbol for HUTCHMED (China) Limited?
  • Does HUTCHMED (China) Limited pay dividends?
  • What sector is HUTCHMED (China) Limited in?
  • What industry is HUTCHMED (China) Limited in?
  • What country is HUTCHMED (China) Limited based in?
  • When did HUTCHMED (China) Limited go public?
  • Is HUTCHMED (China) Limited in the S&P 500?
  • Is HUTCHMED (China) Limited in the NASDAQ 100?
  • Is HUTCHMED (China) Limited in the Dow Jones?
  • When was HUTCHMED (China) Limited's last earnings report?
  • When does HUTCHMED (China) Limited report earnings?
  • Should I buy HUTCHMED (China) Limited stock now?

What is the ticker symbol for HUTCHMED (China) Limited?

The ticker symbol for HUTCHMED (China) Limited is NASDAQ:HCM

Does HUTCHMED (China) Limited pay dividends?

No, HUTCHMED (China) Limited does not pay dividends

What sector is HUTCHMED (China) Limited in?

HUTCHMED (China) Limited is in the Healthcare sector

What industry is HUTCHMED (China) Limited in?

HUTCHMED (China) Limited is in the Drug Manufacturers - Specialty & Generic industry

What country is HUTCHMED (China) Limited based in?

HUTCHMED (China) Limited is headquartered in Hong Kong

When did HUTCHMED (China) Limited go public?

HUTCHMED (China) Limited's initial public offering (IPO) was on March 16, 2016

Is HUTCHMED (China) Limited in the S&P 500?

No, HUTCHMED (China) Limited is not included in the S&P 500 index

Is HUTCHMED (China) Limited in the NASDAQ 100?

No, HUTCHMED (China) Limited is not included in the NASDAQ 100 index

Is HUTCHMED (China) Limited in the Dow Jones?

No, HUTCHMED (China) Limited is not included in the Dow Jones index

When was HUTCHMED (China) Limited's last earnings report?

HUTCHMED (China) Limited's most recent earnings report was on Jul 31, 2024

When does HUTCHMED (China) Limited report earnings?

The next expected earnings date for HUTCHMED (China) Limited is Feb 28, 2025

Should I buy HUTCHMED (China) Limited stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions